

# Index

## A

Active pharmaceutical ingredient (API), 3, 8  
Aminobutanol, 202  
1-Aminocyclopropanecarboxylic acid (ACCA), 96  
Aminonon-8-enoic acid, 100  
Amino-2-vinylcyclopropanecarboxylic acid, 96  
5-Aminothiazolo[4,5-*d*]pyrimidine-2,7-(3*H*,6*H*)-dione, 7  
5-Aminothiazolo[4,5-*d*]pyrimidine-2(3*H*)-thione, 12  
5-Amino-3-(tri-*O*-benzoyl- $\beta$ -*D*-ribofuranosyl)-3*H*-thiazolo[4,5-*d*]pyrimidin-2,7-dione, 7  
Anticancer drugs, 209, 257  
Antiretroviral therapy (ART), 189  
Aryl glycosides, 34  
Arylalanes, 46  
Asymmetric synthesis, 113  
Atherosclerosis, 117  
Atorvastatin, 113, 118, 127, 153–167

## B

3-(Benzyloxy)-4-oxo-4*H*-pyran-2-carbaldehyde, 199  
BILN 2061, 89, 94, 95  
Bis-silyl acetamide (BSA), 15  
Breast cancer, 209, 220, 266  
5-Bromopyrimidine-2,4-diamine, 11  
Butyl 6-cyano-(5*R*)-hydroxy-3-oxohexanoate, 134

## C

Canagliflozin, 29, 31, 39, 43  
Cancer, 54, 212, 220, 257, 266  
Carbamoyl pyridone, 187  
Cardiovascular diseases, 117, 119  
Catalysis, 23, 76, 113, 127, 163, 263  
Cerivastatin, 120  
Cholesterol, 117, 120  
Citronellol, 262  
Comanic acid, 197  
Compactin, 117  
Coronamic acid, 98  
Coronary heart disease, 117–120  
Coupling reactions, transition-metal-mediated, 209  
Cytidine, functionalization, 59, 65

## D

Dapagliflozin, 29, 31, 35, 43  
2-Deoxyribose-5-phosphate aldolase (DERA), 134  
Diabetes, type 2, 29, 31, 42  
2,6-Diaminopyrimidin-4(3*H*)-one, 8  
Diarylzinc, 43  
Diketoreductase, 127  
Direct-acting antivirals (DAAs), 56  
Dolutegravir, 187

## E

Empagliflozin, 31, 37  
Eribulin, 209, 218, 266  
Ertugliflozin, 29, 31, 39  
Ethyl 4-chloro-3-oxobutanoate, 196

Ethyl glycinate, 96

Ezetimib, 120

## F

Fluorination, 51, 58, 74, 85, 122

Fluvastatin, 113, 118, 151

Fragment coupling, 209

## G

Glioblastoma, 258

Gluconolactones, 33

Glucose dehydrogenase, 128

Glycine imines, 96

Glycosylation, 1  
carbon, 29, 42

## H

Halaven, 209

*Halichondria okadai*, 209, 213

Halichondrin, 209, 212

Hepatitis C virus, 51, 89

Heterocycles, 1, 113

HIV-1 integrase inhibitor, 187

reverse transcriptase, 189

Homohalichondrin, 209, 214

Horner–Wadsworth–Emmons (HWE) reaction,  
253, 257

Hoveyda–Grubbs catalyst, 255

4-Hydroxy-7-methoxyquinolines, 98

3-Hydroxy-3-methylglutaryl-coenzyme A  
(HMG-CoA) reductase, 117

Hypercholesterolemia, 117, 181

## I

Indoles, 113

Integrase inhibitors, 187, 190

Integrase strand transfer inhibitors (INSTIs),  
187, 189

Interferons, 2, 54, 58, 91

Ipragliflozin, 29, 31

Isatoribine, 2

## L

Lipase, immobilized, 1, 21

Liver cirrhosis, 55, 89

Lovastatin, 117

Low-density lipoprotein cholesterol  
(LDL-C), 117

Luseogliflozin, 29, 31, 35

## M

Macrocyclic peptides, 89

Macrolides, 209

Marine natural products, 209

Melanoma, 213, 214, 220

Methyl 4-methoxy-3-oxobutanoate, 194, 199

Methyl *tert*-butyl ether (MTBE) 143

Mevastatin, 117

ML-236B, 117

MWCNTs, 143

Myalgia, 120

## N

Non-nucleosidic reverse transcriptase inhibitor  
(NNRTI), 189

Norhalichondrin, 209, 213

Nozaki–Hiyama–Kishi reaction, 209, 255

NS3/NS4A protease inhibitors, 89

Nucleoside/nucleotide reverse transcriptase  
inhibitors (NRTIs), 189

Nucleosides, 64  
synthesis, 51

## O

Okadaic acid, 213

Omura–Sharma–Swern oxidation, 60, 65

## P

Paritaprevir, 92

Peptides, macrocyclic, 89

Peptidomimetic inhibitors, 92

*Phakellia carteri*, 213

Phosphoramidates, synthesis, 51

Pitavastatin, 118, 120, 174

Polyether, 209

Potassium xanthogenate, 12

Pravastatin, 118

Process development, 209

Pyrimidine-2,4-diamine, 9, 11

Pyrimidines, 113

Pyrroles, 113, 120, 153, 181

Pyrrolidine, 106

Pyrroloquinoline quinone, 139

## Q

Quinolines, 98, 113, 120, 175, 181

## R

Reproducibility, 5

Reverse transcriptase, 189

Rhabdomyolysis, 118  
Ribavirin, 55, 57  
Ribofuranose, 7, 18, 67  
Ring-closing metathesis (RCM), 101  
RNA-dependent RNA polymerase (RdRp)  
inhibitors, 56  
Robustness, 5  
Rosuvastatin, 118, 120, 167  
Ruthenacyclopentene, 106

**S**

Scale-up, 209  
Simeprevir, 92  
Simvastatin, 118, 120  
Sodium-coupled glucose cotransporter  
2 (SGLT-2) inhibitors, 29, 31  
Sofosbuvir, 51  
Sotagliflozin, 29, 31, 40  
Statins, 113  
Structure-activity relationships, 209

Subtilisin, 98  
Super-statins, 113, 118  
hepatoselective, 119

**T**

Tetra-*O*-acetyl- $\beta$ -D-ribofuranose, 2  
Thiazolidine-2,4-dione, 9  
Thiazolo[4,5-*d*]pyrimidine nucleoside, 2  
Tofogliflozin, 29

**V**

Vinylcyclopropanes, 105  
Viruses, 51, 89, 189  
HCV, 51, 54, 89, 91  
HIV, 187, 189

**X**

Xanthogenate, 12